In the race for global market share of its obesity and diabetes blockbuster semaglutide, Novo Nordisk is expanding production in Europe.

Flagship Pioneering has committed US$50m to launch Quotient Therapeutics that links genetic variation at  cellular level with disease by Nanoseq, a sequencing method licenced from the Wellcome Sanger Institute.

Cambridge-based Enhanc3D Genomics announced the appointment of Hazel Jones as Chief Operating Officer  at beginning of November.

Finnish protein maker Solar Foods has closed an oversubscribed €8M Series B financing and will expand Solein protein production and support the construction of a commercial production plant.

The Budget Committee of the German Bundestag has announced to channel €38m in funding into the sustainable protein transition next year.

German precision fermentation specialist MicroHarvest GmbH has launched a single-cell protein pilot plant in Lison with an initial capacity of 25kg per day.

The biotech company Cellaïon, based in the Walloon biotechnology valley in Mont-St-Guibert, Belgium, has appointed a new CEO: Dr James Neil Phillips has taken on the role, succeeding Cellaïon’s founder Etienne Sokal.

Due to the global niche character of pharmaceutical biotechnology, research collaborations and market entries on an international level are essential. Agility and market ­knowledge are ­required to maintain an overview in a rapidly evolving environment and to initiate a ­sustainable internationalisation process.

The Innovative Medicine Initiative 2 JU-funded €25m project COMBINE is joining forces with  CARB-X & CAIRD, iiCON and Pharmacology Discovery Services to improve in vivo antibiotics testing.

Dutch VectorY Tx BV has closed one of this yers’s largest Series A financing rounds in Europe at €129m to push its vecorised antibody pipeline in CNS proteinopathies.